– Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 –
– Phase 1 clinical trial expected to initiate in
– Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 –
– Phase 1 clinical trial expected to initiate in the first half of 2021 –
– Company to host virtual KOL event Wednesday, Dec. 15 at 4:30 p.m. ET –
WALTHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (NASDAQ:TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of two posters related to its lead liquid tumor candidates TSC-100 and TSC-101. The posters were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. TSC-100 and TSC-101 are TCR-T cell products directed against the minor histocompatibility antigens HA-1 and HA-2, respectively, which are found only on blood cells. TScan is developing these products to prevent relapse following hematopoietic cell transplant (HCT) in myeloid leukemia. The Company plans to file investigational new drug applications (INDs) for both programs before the end of 2021. A copy of each of the posters is available via TScan's website at http://www.tscan.com/technology/publications/.
As previously announced, the Company's poster presentations include the following:
Presenter: Shrikanta Chattopadhyay, M.D., MBBS, TScan Therapeutics
Author: Chattopadhyay et al.
Poster Number: 3863
Session: Cellular Immunotherapies: Clinical
Presenter: Gavin MacBeath, Ph.D., TScan Therapeutics
Author: Nayar et al.
Poster Number: 1704
Session: Cellular Immunotherapies: Basic and Translational
Recent Comments